Nanjing Hicin Pharmaceutical: Summary of Non-Operating Fund Occupancy and Other Related Fund Transactions for January-June 2024.
Nanjing Hicin Pharmaceutical: Announcement regarding the change of company name and operation scope of a wholly-owned subsidiary.
Nanjing Hicin Pharmaceutical: Announcement on the Progress of Providing Guarantees to Wholly-owned Subsidiaries.
Nanjing Hicin Pharmaceutical: Announcement Regarding the Resignation and Appointment of Deputy General Managers.
Nanjing Hicin Pharmaceutical: Announcement Regarding Company's Receipt of Approval Notice for Listing Application of Active Pharmaceutical Ingredient
Nanjing Hicin Pharmaceutical: Announcement on the pharmaceutical registration approval of propofol and tenofovir disoproxil fumarate tablets of the company.
Nanjing Hicin Pharmaceutical: Legal Opinion of Jiangsu Century Tongren Law Firm on the Company's 2023 Annual General Meeting of Shareholders
Nanjing Hicin Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Haichen Pharmaceutical: 2023 Financial Results Report
Haichen Pharmaceutical: Report of the Board of Directors and Audit Committee on the performance of supervisory duties by annual auditors
Haichen Pharmaceutical: 2023 Internal Control Evaluation Report
Haichen Pharmaceutical: 2024 Financial Budget Report
Haichen Pharmaceutical: Summary table on the use of non-operating capital and other related capital transactions in 2023
Haichen Pharmaceutical: Notice of the 2023 Annual General Meeting of Shareholders
Haichen Pharmaceutical: Announcement on preparation for depreciation of calculated assets
Haichen Pharmaceutical: Special System for Selecting and Hiring Accounting Firms (April 2024)
Haichen Pharmaceutical: Announcement on holding an online briefing on the 2023 annual results
Haichen Pharmaceutical: Announcement on the Company\'s Obtaining Drug Registration Approval for Fibustel Tablets
Haichen Pharmaceutical: Rules of Procedure for the Nomination Committee of the Board of Directors (December 2023)
Haichen Pharmaceutical: Rules of Procedure for the Audit Committee of the Board of Directors (December 2023)
No Data